Forecasting disease progression

About us

We are an AI-driven precision medicine company developing a multimodal prognostic platform to forecast disease progression in age-related disorders. Our forecasts provide new tools to physicians for improved patient care and to pharmaceutical companies for faster drug development. Our current applications are in Alzheimer's disease and feature AD-Px prognostic engine.

Foresight™️ - Our Predictive Platform


Our platform can leverage multiple sources of data (imaging, genetic, phenotypic, molecular and clinical variables) to better characterize individuals.

High precision targeting

We are able to rapidly and precisely target subgroups of interest in large, heterogeneous populations.

Highly actionable insights

Our digital biomarkers are highly specific and thoroughly validated, making them ready for action in any clinical setting.

To learn more, visit our Publications page!

Latest News

[Podcast] Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?

May 31, 2024 | North Carolina, USA | Listen to Podcast

Perceiv AI Raises the Bar with ISO 27001 Certification

May 7, 2024 | Montreal, Canada | Press release

Presentation of AD-Px™ to accelerate trials by reducing screen failure rate at the AD/PD conference

March 9, 2024 | Lisbon, Portugal | See presentation

Perceiv AI Partners with Alleo Labs to Optimize Clinical Trials Using Advanced AI and Prognostic Biomarkers

January 8, 2024 | San Francisco, USA | Press release

Perceiv AI Achieves HIPAA Compliance, Reinforcing Commitment to Data Security and Privacy

November 28, 2023 | Montreal, Canada | Press release

New results presented at CTAD 2023 "Reducing screen failure rates due to biomarker cut-offs in early Alzheimer's disease trials using a prognostic model"

October 24, 2023 | Clinical Trials on Alzheimer's Disease conference (CTAD) | Poster


Perceiv AI Joins Johnson & Johnson Innovation–JLABS Global Network to Accelerate Precision Medicine Platform Development

June 21, 2023 | Toronto, Canada | Annoucement

Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort

January 17, 2023 | Boston, USA | Annoucement

Find all our past news and announcements in our Newsroom!

Meet our Team

Christian Dansereau, Ph.D.

CEO & Founder


César Laurent, Ph.D.

CTO & Founder


Angela Tam, Ph.D.

Senior Scientist


Adrián Noriega de la Colina, 

M.D., Ph.D.

Clinical and Regulatory Lead


Maxime Jacques, M.A.Sc

Software Engineer

Christine Newton, C.P.A.

VP Finance

Meet our Advisors

Yoshua Bengio, Ph.D.

Full Professor at Université de Montréal,

Founder and Scientific Director of Mila,

Scientific Director of IVADO


Serge Gauthier, M.D.

Full Professor at McGill University,

Director of the Alzheimer Disease and Related Disorders Research Unit, Douglas Research Centre


Richard H. Stark, M.S.

Physicist, Entrepreneur & Investor Former Executive at Varian, ViewRay and Elekta


Betsabeh Madani Hermann, M.B.A.

Healthcare executive & investor,

Global Head of Research



Partners & Collaborators

JLABS J&J innovation 

CCNA - Canadian Consortium on Neurodegeneration in Aging
Acasti Pharma Inc.
vTv Therapeutics Inc.
Montreal Heart Institute - Institut de Cardiologie de Montréal
DalCor Pharmaceuticals
McGill University

Supported by

Mila - Quebec AI Institute
CQDM - Consortium de recherche biopharmaceutique
CLSI - California Life Sciences Institute
CTA - Canadian Technology Accelerators
CTS - Campus des Technologies de la Santé
District 3 Innovation Hub